← Back to catalogue

Maternal Control - Level 2 (maternal Control 2)

FDA UDI

Class I (US FDA UDI)

by Randox Laboratories, Ltd.

Identity

Trade Name
MATERNAL CONTROL - LEVEL 2 (MATERNAL CONTROL 2) FDA UDI
Generic Name
Trisomy 21-risk hormone IVD, control FDA UDI
Device Name
This product is intended for in vitro use in the quality control of Alpha-fetoprotein, Free Beta HCG, Free Estriol, Human Chorionic Gonadotrophin, Inhibin A and PAPP-A methods on clinical chemistry systems. FDA UDI
Model / Reference
MSS5025 FDA UDI
Description
This product is intended for in vitro use in the quality control of Alpha-fetoprotein, Free Beta HCG, Free Estriol, Human Chorionic Gonadotrophin, Inhibin A and PAPP-A methods on clinical chemistry systems. FDA UDI

Identifiers

Catalog Number
MSS5025 FDA UDI
Primary DI / UDI-DI
05055273217582 FDA UDI
FDA Product Code
JJY FDA UDI
GMDN Term
Trisomy 21-risk hormone IVD, control FDA UDI

Classification

Device Class
Class I FDA UDI
Regulation Number
862.1660 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

Yes

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

Yes

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

Yes

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

Yes

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

No

FDA UDI

Category: Trisomy 21-risk hormone IVD, control

Maternal Control - Level 2 (maternal Control 2) by Randox Laboratories, Ltd. — Class I — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Trisomy 21-risk hormone IVD, control.

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (1)

  • FDA UDI 91bb75f9-e4b6-4d34-b052-180f21020739 36 fields · synced May 31, 2026